Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study.
Alexandra LadouceurThomas BarnetcheGael MouterdeAlice TisonSamuel BitounSorilla PreyCaroline DutriauxEmilie GerardAnne Pham-LedardMarie Beylot-BarryMaeva ZysmanRémi VeillonCharlotte DomblidesAmaury DasteMarine Gross-GoupilBaptiste SionneauFelix LefortMathieu LarroquetteChristophe RichezMarie-Elise TruchetetThierry SchaeverbekeMarie KostinePublished in: RMD open (2023)
In this first observational study of ICI-IA patients rechallenged with ICI, about half of the patients experienced ICI-IA flare/recurrence with a similar phenotype but occurring earlier than the initial ICI-IA, warranting close monitoring during the first month of retreatment. Risk of flare did not differ according to baseline immunosuppressive treatment at the time of rechallenge.